Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports an increase in the American Depositary Shares (ADSs) interest of Mr. D E Troy. This increase resulted from the re-investment of the dividend paid to shareholders on April 12, 2012, at a price of $45.47 per ADS. The total number of ADSs held by Mr. Troy following this transaction is 425,543.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific insider transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total ADS holdings of Mr. D E Troy (425,543) following the dividend reinvestment.
- Confirm the transaction price of $45.47 per ADS used for the reinvestment.
- Note the dividend payment date of April 12, 2012, which triggered this transaction.
- Understand that this filing does not contain quarterly or annual financial results.